Angle Plc (ANPCY) 15.7800 $ANPCY
Medical University of Vienna Research Demonstrates Value of ANGLE plc's 'Blood Biopsy' Technology
Business Wire - Tue Apr 21, 6:30AM CDT
ANGLE plc (AIM:AGL OTCQX:ANPCY), a UK-based medical diagnostics company with pioneering products for cancer diagnostics and fetal health, announce a poster presentation by researchers from the Medical University of Vienna detailing the utility of its lead product, the Parsortix cell separation system, in the detection of ovarian and breast cancer. The poster will be presented at the American Association for Cancer Research Annual Meeting April 18-22.
ANGLE plc Updates Results on Ovarian Cancer Study
PR Newswire - Tue Apr 21, 5:38AM CDT
ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is delighted to announce that the Medical University of Vienna, one of its key opinion leaders, has published highly encouraging results in support of the use of ANGLE's Parsortix system in the detection of ovarian cancer.
Results From The Sidney Kimmel Cancer Center At Thomas Jefferson University
PR Newswire - Mon Apr 20, 4:59AM CDT
ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is pleased to announce that the Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, one of its key opinion leaders, has published results of its work evaluating the potential for ANGLE's Parsortix system to be used in single cell analysis for breast cancer.
Liquid Biopsy: An Emerging Market for Radically Improved Cancer Management
M2 - Mon Mar 30, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5jpsd4/liquid_biopsy_an) has announced the addition of the "Liquid Biopsy: An Emerging Market for Radically Improved Cancer Management" report to their offering. Cancer diagnostics based on measuring biomarkers in tissue samples has already in the past decade provided revolutionary advances in diagnosis, prognosis, and therapy selection. A major drawback of the tissue-based approach centers on the need for invasive surgical procedures in sample collection, which in a great many instances preclude following the progression or regression of disease during therapy. In recent years, an impressive number of cancer biomarker researchers have turned their attention to the analysis of markers present in biological fluids, which can be collected with minimal invasiveness and permit following the disease over time. This highly dynamic field has come to be called liquid biopsy. In the past few years a significant and growing number of startups and several major companies have taken up the challenge of commercializing and offering liquid biopsy products and services to the market These procedures, for the most part, query blood samples for information to be gleaned from circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) fragments, and extracellular vesicles (EVs). CTCs have the longest history as subjects for liquid biopsy. Indeed, one decade-old commercial product has already garnered FDA approval for in vitro diagnostic use. Circulating tumor DNA, a more recent entry on the liquid biopsy scene, is fast becoming an alternative or adjunct to CTC assays. EVs are the newest and least developed of the three liquid biopsy sample sources, and while highly promising, their ultimate value has yet to be fully established. The report delves deeply into recent progress and emerging trends in this highly dynamic area of research and commerce. Key Topics Covered: - Executive Summary - Chapter Introduction - Chapter Background and History - Chapter Liquid Biopsy Research - Chapter Commercial Aspects of Liquid Biopsy - Market Dynamics - Liquid Biopsy Trends - Interview Transcripts Companies Mentioned - AdnaGen - Agena Bioscience - Angle plc - ApoCell - BioFluidica - Biocept - Boreal Genomics - Chronix Biomedical - Circulating tumor DNA (ctDNA) - Clearbridge BioMedics - Cynvenio - CytoTrack - Cytolumina Technologies Corp. - Diagnologix LLC - Epic Sciences - Exosome Diagnostics - Exosome Sciences Inc. - Extracellular vesicles (EVs) - Fluxion Biosciences - Genomic Health - Molecular MD - Myriad Genetics - Natera - Personal Genome Diagnostics - Qiagen - Rarecells SAS - SRI International - Silicon Biosystems - Sysmex Inostics - Trovagene For more information visit http://www.researchandmarkets.com/research/5j..._biopsy_an
MYGN: 34.25 (+0.27), GHDX: 27.85 (+0.61)
S&P Capital IQ Initiates Coverage on ANGLE Plc in S&P Capital IQ Factual Stock Reports
PR Newswire - Mon Mar 16, 11:59AM CDT
S&P Capital IQ (MHFI) announced today that it has commenced Factual Stock Report coverage on ANGLE Plc.
MHFI: 107.22 (+1.52)
ANGLE plc ("Angle" or "the Company"
Collaboration With MD Anderson Cancer Center On Colorectal Cancer
PR Newswire - Mon Feb 16, 12:34PM CST
ANGLE plc (AIM:AGL and OTCQX:ANPCY), the specialist medtech company, is delighted to announce a collaboration with the MD Anderson Cancer Center to investigate the clinical use of ANGLE's Parsortix system as a companion diagnostic in colorectal cancer.
ANGLE plc ("the Company" Patient Data Shows "Unprecedented Sensitivity And Specificity" For Parsortix Ovarian Cancer Clinical Application
PR Newswire - Tue Jan 27, 11:37AM CST
ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company, is delighted to announce that the Medical University of Vienna, one of its key opinion leaders, has reported highly convincing patient data in support of the use of ANGLE's Parsortix system in the detection of ovarian cancer.
ANGLE plc ("ANGLE" Or "The Company" Corporate Collaboration With Large Pharmaceutical Company
PR Newswire - Thu Jan 08, 6:40AM CST
ANGLE plc (AIM:AGL and OTCQX:ANPCY), the specialist medtech company, is delighted to announce that it has agreed a collaboration with a subsidiary of a large pharmaceutical company (the "Collaborator" to investigate the combination of ANGLE's Parsortix circulating tumour cell (CTC) harvesting platform with the Collaborator's single cell analysis system.
OTC Markets Group Welcomes ANGLE to OTCQX®
PR Newswire - Fri Oct 31, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced ANGLE plc (AIM: AGL; OTCQX: ANPCY), a specialist medical diagnostics company, has qualified to have its American Depositary Receipts (ADRs) trade on OTCQX®, the best marketplace.
Medical University of Vienna Research Demonstrates Value of ANGLE plc's 'Blood Biopsy' Technology
Business Wire - Tue Apr 21, 6:30AM CDT
ANGLE plc (AIM:AGL OTCQX:ANPCY), a UK-based medical diagnostics company with pioneering products for cancer diagnostics and fetal health, announce a poster presentation by researchers from the Medical University of Vienna detailing the utility of its lead product, the Parsortix cell separation system, in the detection of ovarian and breast cancer. The poster will be presented at the American Association for Cancer Research Annual Meeting April 18-22.
ANGLE plc Updates Results on Ovarian Cancer Study
PR Newswire - Tue Apr 21, 5:38AM CDT
ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is delighted to announce that the Medical University of Vienna, one of its key opinion leaders, has published highly encouraging results in support of the use of ANGLE's Parsortix system in the detection of ovarian cancer.
Results From The Sidney Kimmel Cancer Center At Thomas Jefferson University
PR Newswire - Mon Apr 20, 4:59AM CDT
ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is pleased to announce that the Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, one of its key opinion leaders, has published results of its work evaluating the potential for ANGLE's Parsortix system to be used in single cell analysis for breast cancer.
Liquid Biopsy: An Emerging Market for Radically Improved Cancer Management
M2 - Mon Mar 30, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5jpsd4/liquid_biopsy_an) has announced the addition of the "Liquid Biopsy: An Emerging Market for Radically Improved Cancer Management" report to their offering. Cancer diagnostics based on measuring biomarkers in tissue samples has already in the past decade provided revolutionary advances in diagnosis, prognosis, and therapy selection. A major drawback of the tissue-based approach centers on the need for invasive surgical procedures in sample collection, which in a great many instances preclude following the progression or regression of disease during therapy. In recent years, an impressive number of cancer biomarker researchers have turned their attention to the analysis of markers present in biological fluids, which can be collected with minimal invasiveness and permit following the disease over time. This highly dynamic field has come to be called liquid biopsy. In the past few years a significant and growing number of startups and several major companies have taken up the challenge of commercializing and offering liquid biopsy products and services to the market These procedures, for the most part, query blood samples for information to be gleaned from circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) fragments, and extracellular vesicles (EVs). CTCs have the longest history as subjects for liquid biopsy. Indeed, one decade-old commercial product has already garnered FDA approval for in vitro diagnostic use. Circulating tumor DNA, a more recent entry on the liquid biopsy scene, is fast becoming an alternative or adjunct to CTC assays. EVs are the newest and least developed of the three liquid biopsy sample sources, and while highly promising, their ultimate value has yet to be fully established. The report delves deeply into recent progress and emerging trends in this highly dynamic area of research and commerce. Key Topics Covered: - Executive Summary - Chapter Introduction - Chapter Background and History - Chapter Liquid Biopsy Research - Chapter Commercial Aspects of Liquid Biopsy - Market Dynamics - Liquid Biopsy Trends - Interview Transcripts Companies Mentioned - AdnaGen - Agena Bioscience - Angle plc - ApoCell - BioFluidica - Biocept - Boreal Genomics - Chronix Biomedical - Circulating tumor DNA (ctDNA) - Clearbridge BioMedics - Cynvenio - CytoTrack - Cytolumina Technologies Corp. - Diagnologix LLC - Epic Sciences - Exosome Diagnostics - Exosome Sciences Inc. - Extracellular vesicles (EVs) - Fluxion Biosciences - Genomic Health - Molecular MD - Myriad Genetics - Natera - Personal Genome Diagnostics - Qiagen - Rarecells SAS - SRI International - Silicon Biosystems - Sysmex Inostics - Trovagene For more information visit http://www.researchandmarkets.com/research/5j..._biopsy_an
MYGN: 34.25 (+0.27), GHDX: 27.85 (+0.61)
S&P Capital IQ Initiates Coverage on ANGLE Plc in S&P Capital IQ Factual Stock Reports
PR Newswire - Mon Mar 16, 11:59AM CDT
S&P Capital IQ (MHFI) announced today that it has commenced Factual Stock Report coverage on ANGLE Plc.
MHFI: 107.22 (+1.52)
ANGLE plc ("Angle" or "the Company"
Collaboration With MD Anderson Cancer Center On Colorectal Cancer PR Newswire - Mon Feb 16, 12:34PM CST
ANGLE plc (AIM:AGL and OTCQX:ANPCY), the specialist medtech company, is delighted to announce a collaboration with the MD Anderson Cancer Center to investigate the clinical use of ANGLE's Parsortix system as a companion diagnostic in colorectal cancer.
ANGLE plc ("the Company"
Patient Data Shows "Unprecedented Sensitivity And Specificity" For Parsortix Ovarian Cancer Clinical Application PR Newswire - Tue Jan 27, 11:37AM CST
ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company, is delighted to announce that the Medical University of Vienna, one of its key opinion leaders, has reported highly convincing patient data in support of the use of ANGLE's Parsortix system in the detection of ovarian cancer.
ANGLE plc ("ANGLE" Or "The Company"
Corporate Collaboration With Large Pharmaceutical Company PR Newswire - Thu Jan 08, 6:40AM CST
ANGLE plc (AIM:AGL and OTCQX:ANPCY), the specialist medtech company, is delighted to announce that it has agreed a collaboration with a subsidiary of a large pharmaceutical company (the "Collaborator"
to investigate the combination of ANGLE's Parsortix circulating tumour cell (CTC) harvesting platform with the Collaborator's single cell analysis system. OTC Markets Group Welcomes ANGLE to OTCQX®
PR Newswire - Fri Oct 31, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced ANGLE plc (AIM: AGL; OTCQX: ANPCY), a specialist medical diagnostics company, has qualified to have its American Depositary Receipts (ADRs) trade on OTCQX®, the best marketplace.
